These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51 related articles for article (PubMed ID: 3308081)
1. Phase I trial of procarbazine as a 5-day continuous infusion in children with central nervous system tumors. van Eys J; Cangir A; Pack R; Baram T Cancer Treat Rep; 1987 Oct; 71(10):973-4. PubMed ID: 3308081 [TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of topotecan for pediatric central nervous system tumors. Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400 [TBL] [Abstract][Full Text] [Related]
3. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Adamson PC; Balis FM; Belasco JE; Lange B; Berg SL; Blaney SM; Craig C; Poplack DG Cancer Res; 1995 Sep; 55(18):4069-72. PubMed ID: 7664282 [TBL] [Abstract][Full Text] [Related]
4. Phase I trial of caracemide using bolus and infusion schedules. Raber MN; Adams F; Kavanagh J; Legha S; Dimery I; Krakoff I Cancer Treat Rep; 1987 Apr; 71(4):349-52. PubMed ID: 3548956 [TBL] [Abstract][Full Text] [Related]
5. Phase I trial of pentamethylmelamine. Ajani JA; Cabanillas FF; Bodey GP Cancer Treat Rep; 1982 May; 66(5):1227-8. PubMed ID: 6805950 [TBL] [Abstract][Full Text] [Related]
6. Pediatric phase I trial of carboplatin: a Childrens Cancer Study Group report. Gaynon PS; Ettinger LJ; Moel D; Siegel SE; Baum ES; Krivit W; Hammond GD Cancer Treat Rep; 1987 Nov; 71(11):1039-42. PubMed ID: 3315195 [TBL] [Abstract][Full Text] [Related]
7. Phase I trial of pentamethylmelamine in patients with previously treated malignancies. Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747 [TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies. Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747 [TBL] [Abstract][Full Text] [Related]
9. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer. Tan CT; Hancock CH; Mondora A; Hoffman NW Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381 [TBL] [Abstract][Full Text] [Related]
10. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325 [TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246 [TBL] [Abstract][Full Text] [Related]
12. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923 [TBL] [Abstract][Full Text] [Related]
13. Phase I trial of pentamethylmelamine: a clinical and pharmacologic study. Ihde DC; Dutcher JS; Young RC; Cordes RS; Barlock AL; Hubbard SM; Jones RB; Boyd MR Cancer Treat Rep; 1981; 65(9-10):755-62. PubMed ID: 6791819 [TBL] [Abstract][Full Text] [Related]
14. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK; Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532 [TBL] [Abstract][Full Text] [Related]
15. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806 [TBL] [Abstract][Full Text] [Related]
16. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies. Hidalgo M; Rodriguez G; Kuhn JG; Brown T; Weiss G; MacGovren JP; Von Hoff DD; Rowinsky EK Clin Cancer Res; 1998 Nov; 4(11):2763-70. PubMed ID: 9829740 [TBL] [Abstract][Full Text] [Related]
17. Phase I-II trial of high-dose epirubicin in patients with lymphoma. Case DC; Gams R; Ervin TJ; Boyd MA; Oldham FB Cancer Res; 1987 Dec; 47(23):6393-6. PubMed ID: 3479245 [TBL] [Abstract][Full Text] [Related]
18. Phase I study of 3-deazauridine in the treatment of adults with solid tumors. Stewart DJ; McCredie KD; Barlogie B; Valdivieso M; Benjamin RS; Burgess MA; Bodey GP Cancer Treat Rep; 1980; 64(12):1295-9. PubMed ID: 7471119 [TBL] [Abstract][Full Text] [Related]
19. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950 [TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Bennett CL; Sinkule JA; Schilsky RL; Senekjian E; Choi KE Cancer Res; 1987 Apr; 47(7):1952-6. PubMed ID: 3815383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]